Tests MCRcI stem cells in people with diffuse coronary artery disease
Checks the safety of MCRcI stem cells given into the heart arteries of adults.
Plain-language title generated from the registry record
Registry title: MCRcI® Stem Cell Treatment for Diffuse Coronary Artery Disease
Key facts
- Where
- Tainan, TaiwanSee the site
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 20 and 80 years old?
Source: NCT04052191, who can take part
Where in Taiwan
- HONYA Medical IncTainan, TaiwanNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Honya Medical Inc
- Trial code
- NCT04052191
- Record updated
- 3 October 2024
- Original description
Safety evaluation of Intra-Coronary Administration of MCRcI® stem cells in Patients with Diffuse Coronary Artery Disease.Read full original descriptionShow less
Intra-Coronary Administration of MCRcI® (Myo-Cardial Regenerative Cellular Injection) Improves Left Ventricular Function in Patients With Diffuse Coronary Artery Disease
Safety evaluation of Intra-Coronary Administration of MCRcI® stem cells in Patients with Diffuse Coronary Artery Disease.
Inclusion: Patients with Diffuse Coronary Artery Disease; Age 20~80; Participants have received proper medication; Canadian Cardiovascular Society class II- IV Angina.
Exclusion: Positive adventitious infection (such as HIV, hepatitis ); History of Myocardial Infarction within past 3 months; Malignant tumor; Severe organ disease with less than 1 year of life expectancy; Chronic kidney disease with CCr<20ml/min; Kiney disease on renal dialysis; Age <20 or >80; Pregnant or breast feeding; Severe aortic or mitral valve narrowing; Short of breath unable to receive PCI examination or treatment; Hematopoietic dysplasia.